Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2016.266 | Hong Kong Childhood Diabetes Registry |
Dr. YAU Ho Chung 游可聰 |
| 2019.442 | Twelve-Year Review on The Screening of Glycosuria in Obese School Children and Adolescents for Early Diagnosis of Type 2 Diabetes Mellitus, A Retrospective Study in Hong Kong | Dr YAU Ho Chung |
| 2020.664 | Symptomatic vitamin D deficiency in children and adolescents: multi-centre experience in Hong Kong | Dr. YAU Ho Chung |
| 2020.085 | Prognosis of severe dysphagia patient with dementia in local hospital |
Dr. YAU Ho Tuen 邱賀端 |
| 2024.166 | The Effectiveness of Horticultural Therapy in Improving the Quality of Life of Patients and the Sense of Satisfaction of Caregivers in Specialized Palliative Care Unit | Ms. YAU Karen Ka Shuen |
| 2019.501 | Patients’ barriers to use Non-vitamin K novel oral anticoagulants in high risk nonvalvular atrial fibrillation patients in General Outpatient Clinic in Hong Kong |
Dr. YAU King Sun 游景新 |
| 2014.072 | Retrospective study of Use of Levetiracetam in Neonates | Dr. Yau Lo Yee |
| 2024.009 | Phenotypic landscape and genotype correlations in patients with SCN1A mutation | Dr YAU Lo Yee |
| 2022.105 | Neuro-modulation in patients with refractory epilepsy – a multicenter study in Hong Kong SAR, China |
Dr. YAU Lo Yee 邱露儀 |
| 2013.462 | A study of operational model efficiency: the improvement on service equality and efficiency in the delivery process of home based rehabilitation service (HBRS), by developing a new route planning system and a new discharge logistic plan, for the poor and | Mr. Yau Ngok |
| 2014.255 | A cross-sectional study of cardio-metabolic risk in Chinese women with Polycystic Ovary Syndrome | Dr Yau Tse Ling |
| 2024.426 | The association of refractive error and deviation control of patients with intermittent exotropia in Hong Kong | Mr. YAU Tsz Him |
| 2025.002 | The Effectiveness of National Early Warning Score (NEWS) 2 in predicting Sudden Cardiac Arrest among Accident and Emergency Department Patients | Mr. YAU Yiu For |
| 2024.091 | Using social norms to promote physical activity among physically inactive college students in China: A randomized controlled trial |
Mr. YE Xinchen 叶欣晨 |
| 2023.215 | Evaluation of the Effectiveness of Irreversible Electroporation for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2019.043 | Image-guided robot-assisted waterjet ablation of the prostate for patients with retention of urine due to benign prostatic obstruction |
Dr. YEE Chi Hang 余知行 |
| 2018.556 | Evaluation of the Effectiveness of High-intensity Focused Ultrasound for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2020.018 | Evaluation of the Effectiveness of Cryotherapy for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2020.019 | Robotic Radical Perineal Prostatectomy for Localized Prostate Cancer: A Feasibility Study |
Dr. YEE Chi Hang 余知行 |
| 2019.535 | Music as an Adjunct for Pain and Anxiety Relief during Urological Procedure: A Randomized Control Trial |
Dr. YEE Chi Hang 余知行 |
| 2016.248 | Prevention of Lymphocele with Floseal in Renal Transplantation: A Multicentre Randomized Controlled Trial |
Dr. YEE Chi Hang 余知行 |
| 2015.613 | The Associations between Severity Level of Lower Urinary Tract Symptoms and Cardiovascular Risk in Male Patients in Hong Kong |
Dr. YEE Chi Hang 余知行 |
| 2017.394 | A Comprehensive Evaluation of the Transgender Population in Hong Kong: An Age-Matched, and Sex- or Preferred Gender-Matched Comparative Observational Study. |
Dr. YEE Chi Hang 余知行 |
| 2016.588 | A Telephone Survey of Lower Urinary Tract Symptoms and Health in Hong Kong |
Dr. YEE Chi Hang 余知行 |
| 2020.659 | Determinants of osteoarthritis outcomes and progression in persons with late-stage knee osteoarthritis over 18 months | Dr. YEE Dennis King Hang |
| 2023.240 | Surgical accuracy and clinical outcomes of image-free versus image-based robotic-assisted total knee arthroplasty | Dr. YEE King Hang |
| 2020.505 | Sterilized 3D PRINTed bone models versus conventional CT imaging for operative visualization for complex fracture repair surgery – A randomized multicentre study |
Dr. YEE King Hang 余敬行醫生 |
| 2018.435 | A Phase 3, multicenter, randomized, open-label, active-controlled study of Trastuzumab Deruxtecan (DS-8201A), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane (DESTINY-Breast03) |
Prof. YEO Winnie 楊明明 |
| 2019.476 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2020.330 | Scalp Cooling Study for the Prevention of Chemotherapy-induced Alopecia in Chinese Breast Cancer Patients |
Prof. YEO Winnie 楊明明教授 |
| 2018.528 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2018.392 | A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859) |
Prof. YEO Winnie 楊明明 |
| 2019.551 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2020.258 | A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. |
Prof. YEO Winnie 楊明明 |
| 2018.363 | A RETROSPECTIVE STUDY ON EFFICACY AND TOLERABILITY OF COMBINATION FLOT CHEMOTHERAPY AS NEOADJUVANT CHEMOTHERAPY IN GASTRIC CANCER PATIENTS |
Prof. YEO Winnie 楊明明 |
| 2015.696 | RETROSPECTIVE REVIEW OF EFFICACY AND TOLERABILITY OF T-DM1 IN ADVANCED HER2+ BREAST CANCER |
Prof. YEO Winnie 楊明明 |
| 2017.169 | Open label single arm study for NEPA [oral fixed-dose combination of 300 mg netupitant and 0.50 mg palonosetron] in Hong Kong oncology patients receiving (neo)-adjuvant chemotherapy treatment consists of adriamycin and cyclophosphamide for breast cancer. | Prof. YEO Winnie |
| 2016.290 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma |
Prof. YEO Winnie 楊明明 |
| 2015.507 | A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119) |
Prof. YEO Winnie 楊明明 |
| 2017.072 | A Prospective Study on the Role of Pharmacogenomic Study in Association with Chemotherapy-Induced Nausea and Vomiting | Prof. YEO Winnie |
| 2014.078 | The prognostic significance of combination of AFP, DCP and AFP L3 as biomarkers in hepatocellular carcinoma | Prof. YEO Winnie |
| 2014.596 | A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepatocellular Carcinoma (HCC) | Prof. YEO Winnie |
| 2014.529 | A randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy | Prof. YEO Winnie |
| 2014.584 | A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer | Prof. YEO Winnie |
| 2017.478 | A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer |
Prof. YEO Winnie 楊明明教授 |
| 2017.262 | A comparison of 24-h dietary recalls and mobile phone food record among Hong Kong Chinese women with early-stage breast cancer |
Prof. YEO Winnie 楊明明 |
| 2015.689 | A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma |
Prof. YEO Winnie 楊明明 |
| 2017.320 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer |
Prof. YEO Winnie 楊明明 |
| 2014.460 | A Retrospective Study to Assess the Role of Prophylactic Anti-viral Therapies for Patients with CD20+ Lymphoma Receiving Anti-B cell Therapies | Prof. YEO Winnie |
| 2016.013 | A Randomized Study to Determine the Efficacy and Tolerability of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese breast cancer patients. |
Prof. YEO Winnie 楊明明 |
Page 251 of 265.